Guiding Drugs to Target-Harboring Organelles: Stretching Drug-Delivery to a Higher Level of Resolution.
Sivan Louzoun-ZadaQais Z JaberMicha FridmanPublished in: Angewandte Chemie (International ed. in English) (2019)
The ratio between the dose of drug required for optimal efficacy and the dose that causes toxicity is referred to as the therapeutic window. This ratio can be increased by directing the drug to the diseased tissue or pathogenic cell. For drugs targeting fungi and malignant cells, the therapeutic window can be further improved by increasing the resolution of drug delivery to the specific organelle that harbors the drug's target. Organelle targeting is challenging and is, therefore, an under-exploited strategy. Here we provide an overview of recent advances in control of the subcellular distribution of small molecules with the focus on chemical modifications. Highlighted are recent examples of active and passive organelle-specific targeting by incorporation of organelle-directing molecular determinants or by chemical modifications of the pharmacophore. The outstanding potential that lies in the development of organelle-specific drugs is becoming increasingly apparent.
Keyphrases
- drug delivery
- cancer therapy
- drug induced
- single molecule
- induced apoptosis
- oxidative stress
- adverse drug
- single cell
- stem cells
- cell cycle arrest
- cell therapy
- drug release
- mesenchymal stem cells
- molecular docking
- computed tomography
- cell death
- risk assessment
- endoplasmic reticulum stress
- electronic health record
- endoplasmic reticulum